{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:57:50Z","timestamp":1775743070509,"version":"3.50.1"},"reference-count":14,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T00:00:00Z","timestamp":1506729600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openophthalmologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOOPHTJ"],"published-print":{"date-parts":[[2017,9,30]]},"abstract":"\n Purpose:<\/jats:title>\n With the advent of more aggressive cytotoxic chemotherapy regimens, the incidence of ocular toxicity due to these drugs is also on the rise. We report a case of Presumed Chemotherapy-Induced optic neuropathy and maculopathy secondary to treatment with cytarabine and daunorubicin for Acute Myeloid Leukaemia (AML).<\/jats:p>\n <\/jats:sec>\n \n Case report:<\/jats:title>\n A 50-year-old man with AML developed sudden decrease in vision in his left eye after three cycles of chemotherapy with cytarabine and daunorubicin. He presented to us six weeks later with bilateral optic atrophy and foveal atrophic changes with early bull\u2019s eye maculopathy. A diagnosis of presumed chemotherapy-induced optic neuropathy with maculopathy was made, and the patient was put on an alternative chemotherapeutic regimen. There was no further decrease in vision on follow up.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n To the best of our knowledge, this is the first report of clinically demonstrable macular toxicity in the form of macular atrophic changes and bull\u2019s eye maculopathy associated with the use of cytarabine and daunorubicin. Early diagnosis and appropriate management of such cases is imperative to prevent further visual deterioration.<\/jats:p>\n <\/jats:sec>","DOI":"10.2174\/1874364101711010298","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T11:42:13Z","timestamp":1507203733000},"page":"298-304","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Presumed Chemotherapy-Induced Optic Neuropathy and Maculopathy: A Case Report"],"prefix":"10.2174","volume":"11","author":[{"given":"David J.","family":"Mathew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anupriya","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheeja Susan","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Schiff D, Kesari S, Wen P. \n Cancer Neurology in Clinical Practice: Neurologic Complications of Cancer and its Treatment 2nd ed. \n \n \n \n 2008.","DOI":"10.1007\/978-1-59745-412-4"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Schachat AP, Markowitz JA, Guyer DR, Burke PJ, Karp JE, Graham ML. \n Ophthalmic manifestations of leukemia. \n Arch Ophthalmol \n 1989; \n 107\n (5)\n : 697-700.","DOI":"10.1001\/archopht.1989.01070010715033"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Khaja WA, Pogrebniak AE, Bolling JP. \n Combined orbital proptosis and exudative retinal detachment as initial manifestations of acute myeloid leukemia. \n J AAPOS \n 2015; \n 19\n (5)\n : 479-82.","DOI":"10.1016\/j.jaapos.2015.05.018"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Voest EE, Neijt JP, Keunen JE, et al. \n Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. \n Cancer Chemother Pharmacol \n 1993; \n 31\n (5)\n : 357-62.","DOI":"10.1007\/BF00686148"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Margileth DA, Poplack DG, Pizzo PA, Leventhal BG. \n Blindness during remission in two patients with acute lymphoblastic leukemia: a possible complication of multimodality therapy. \n Cancer \n 1977; \n 39\n (1)\n : 58-61.","DOI":"10.1002\/1097-0142(197701)39:1<58::AID-CNCR2820390111>3.0.CO;2-5"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Schmid KE, Kornek GV, Scheithauer W, Binder S. \n Update on ocular complications of systemic cancer chemotherapy. \n Surv Ophthalmol \n 2006; \n 51\n (1)\n : 19-40.","DOI":"10.1016\/j.survophthal.2005.11.001"},{"key":"ref7","unstructured":"Vogler WR, Winton EF, Heffner LT, et al. \n Ophthalmological and other toxicities related to cytosine arabinoside and total body irradiation as preparative regimen for bone marrow transplantation. \n Bone Marrow Transplant \n 1990; \n 6\n (6)\n : 405-9."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Millay RH, Klein ML, Shults WT, Dahlborg SA, Neuwelt EA. \n Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier. \n Am J Ophthalmol \n 1986; \n 102\n (5)\n : 626-32.","DOI":"10.1016\/0002-9394(86)90536-2"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Steinhorst UH, Hatchell DL, Chen EP, Machemer R. \n Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression. \n Graefes Arch Clin Exp Ophthalmol \n 1993; \n 231\n (10)\n : 591-4.","DOI":"10.1007\/BF00936524"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Van Bol L, Alami A, Benghiat FS, Rasquin F. \n Spectral domain optical coherence tomography findings in early deferoxamine maculopathy: report of two cases. \n Retin Cases Brief Rep \n 2014; \n 8\n (2)\n : 97-102.","DOI":"10.1097\/ICB.0000000000000013"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Gelman R, Kiss S, Tsang SH. \n Multimodal imaging in a case of deferoxamine-induced maculopathy. \n Retin Cases Brief Rep \n 2014; \n 8\n (4)\n : 306-9.","DOI":"10.1097\/ICB.0000000000000059"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Kumar A, Nainiwal S, Choudhary I, Tewari HK, Verma LK. \n Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery. \n Clin Experiment Ophthalmol \n 2002; \n 30\n (5)\n : 348-51.","DOI":"10.1046\/j.1442-9071.2002.00554.x"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Chhablani J, Nieto A, Hou H, et al. \n Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system. \n Invest Ophthalmol Vis Sci \n 2013; \n 54\n (2)\n : 1268-79.","DOI":"10.1167\/iovs.12-11172"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Varma D, Sihota R, Agarwal HC. \n Evaluation of efficacy and safety of daunorubicin in glaucoma filtering surgery. \n Eye (Lond) \n 2007; \n 21\n (6)\n : 784-8.","DOI":"10.1038\/sj.eye.6702328"}],"container-title":["The Open Ophthalmology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openophthalmologyjournal.com\/contents\/volumes\/V11\/TOOPHTJ-11-298\/TOOPHTJ-11-298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openophthalmologyjournal.com\/contents\/volumes\/V11\/TOOPHTJ-11-298\/TOOPHTJ-11-298.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openophthalmologyjournal.com\/contents\/volumes\/V11\/TOOPHTJ-11-298\/TOOPHTJ-11-298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T06:31:57Z","timestamp":1555309917000},"score":1,"resource":{"primary":{"URL":"https:\/\/openophthalmologyjournal.com\/VOLUME\/11\/PAGE\/298\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,30]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,9,30]]}},"alternative-id":["TOOPHTJ-11-298"],"URL":"https:\/\/doi.org\/10.2174\/1874364101711010298","relation":{},"ISSN":["1874-3641"],"issn-type":[{"value":"1874-3641","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}